Georgia CommonsHB 352: Georgia Gestational Diabetes Management Act; enact
Versión Enrolled, la más reciente que tiene LegiScan · Última acción: 14 de mayo de 2025 · Passed
El texto tal como lo tiene LegiScan, leído del PDF que publica la legislatura, sin los números de línea del margen, los encabezados ni los pies de página. Aquí los saltos de línea se unen en párrafos; no se cambia ninguna palabra. El texto está en inglés.
Las palabras subrayadas son las que el proyecto de ley agrega a la ley vigente y las tachadas son las que elimina, tal como las muestra el proyecto impreso.
House Bill 352 (AS PASSED HOUSE AND SENATE)
By: Representatives Seabaugh of the 34th, Cooper of the 45th, Mathis of the 133rd, Taylor of the 173rd, Reese of the 140th, and others
A BILL TO BE ENTITLED
AN ACT
To amend Code Section 49-4-159.4 of the Official Code of Georgia Annotated, relating to coverage for continuous glucose monitors, so as to revise coverage criteria to include Medicaid recipients with gestational diabetes; to provide for related matters; to provide for a short title; to repeal conflicting laws; and for other purposes.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION 1.
This Act shall be known and may be cited as the "Georgia Gestational Diabetes Management Act."
SECTION 2.
Code Section 49-4-159.4 of the Official Code of Georgia Annotated, relating to coverage for continuous glucose monitors, is amended by revising subsection (a) as follows: "(a) On and after July 1, 2023 2025, the department shall include coverage for continuous glucose monitors as a benefit under Medicaid via the most cost-effective benefit delivery channel. The criteria for such coverage shall be updated to align with current standards of care and shall include, but shall not be limited to, requirements that:
(1) The recipient has been diagnosed with diabetes mellitus by a treating practitioner;
(2) The recipient's treating practitioner has concluded that the recipient or the recipient's caregiver has had sufficient training in using a continuous glucose monitor as evidenced by the provision of a prescription therefor; and
(3) The recipient:
(A) Is treated with at least one daily administration of insulin; or
(B) Has gestational diabetes; or
(C) Has a history of problematic hypoglycemia with documentation of at least one of the following:
(i) Recurrent level 2 hypoglycemic events (glucose less than 54 mg/dL (3.0 mmol/L)) that persist despite two or more attempts to adjust medication, modify the diabetes treatment plan, or both; or
(ii) A history of a level 3 hypoglycemic event (glucose less than 54 mg/dL (3.0 mmol/L)) characterized by altered mental or physical state requiring third-party assistance for treatment for hypoglycemia."
SECTION 3.
All laws and parts of laws in conflict with this Act are repealed.